Salvage Surgery Post Definitive Chemoradiotherapy and Durvalumab for Lung Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 33373589.
- Also identified by DOI 10.1016/j.athoracsur.2020.09.083.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although concurrent chemoradiotherapy (CRT) followed by consolidation immunotherapy considerably improves the duration of survival in patients with unresectable stage III non-small cell lung cancer (NSCLC), few data are available on the management of local relapse after therapy. We present a patient with initially unresectable NSCLC who underwent a right upper lobectomy with reconstruction of the bronchus and pulmonary artery after definitive CRT, followed by consolidation durvalumab. No postoperative complications occurred, and he was recurrence-free at the 10-month follow-up. Salvage surgery might be a viable option for local relapse of NSCLC treated with definitive CRT and durvalumab.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Neoplasm Staging
- Salvage Therapy